ACTG 330--SAFETY & PHARMACOKINETICS OF 1592U89 ALONE VS COMBINATION--PEDIATRIC

齐多夫定(ZdV)、去氢肌苷(Ddi)、司他夫定(D4T)和拉米夫定 (3TC)，通常用作单一制剂，也可组合用于 儿童艾滋病毒感染的治疗。积累的信息表明 然而，两种或两种以上抗逆转录病毒药物的联合治疗， 从长远来看，可能比单一药物疗法更有希望 艾滋病毒感染的管理。此外，作为对常见疾病的抗性 药物的出现，研究新的 可用于治疗感染艾滋病毒的婴儿和儿童的药物。 1592u89是一种核苷类似物，其抗HIV活性类似于 ZDV。这种新药的体外研究表明，抗药性 对艾滋病毒出现缓慢，并对其他抗逆转录病毒药物产生交叉耐药性 此外，1592u89可能对ddi、3TC和d4T有协同作用。早些时候 成人和儿科研究表明，几乎没有明显的毒性 减少艾滋病毒病毒载量。

Zidovudine (ZDV), didanosine (ddI), stavudine (d4T), and lamivudine (3TC), are commonly used as single agents as well as in combination for treatment of HIV infection in children. Accumulating information suggests that combination therapy with two or more antiretroviral agents, however, may hold more promise than single-agent therapy in the long term management of HIV infection. In addition, as resistance to common medications occurs, it becomes increasingly important to investigate new medications that may be used to treat HIV-infected infants and children. 1592u89 is a nucleoside analog with activity against HIV similar to that of ZDV. In vitro studies of this new medication suggest that resistance to HIV is slow to emerge, and cross-resistance to other antiretrovirals rare; further 1592u89 may act synergistically to ddI, 3TC, and d4T. Early adult and pediatric studies demonstrated few toxicities with significant reduction in HIV viral load.